NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/26/2023
Back to search
Official data from USPTO
LEUKOCARE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
LEUKOCARE
ST13
US500000097000722Class
1, 5, 9, 10, 42
Filing
97000722
Registration
7172256
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
09/26/2023
Trademark type
Word
Nice classes
1, 5, 9, 10, 42
Filing date
08/29/2021
Registration date
09/26/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/26/2023
Last transaction
09/26/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
99
Owner location
Martinsried/München, DE
Examiner
WOLFSEN, CHRISTIANNE LISBETH
Law office
O20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Leukocare AG
Representatives
Catherine F. Hoffman DICKINSON WRIGHT PLLC
Technical classification
Nice Classes
Class 1Class 5Class 9Class 10Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Proteins in purified raw form for scientific and medical research purposes; Proteins for industrial use by the pharmaceutical industry; Proteins for use in manufacture
Class 5
Pharmaceutical productsin particular chemical preparations for medical purposesfor treating cancerautoimmune diseasescardiovascular diseasesneurodegenerative diseasesinfectious diseasesendocrine diseasesgastrointestinal diseasesnephrological diseasesrespiratory diseasesophthalmological diseases; pharmaceutical preparations in the form of antibodies for the treatment of cancerautoimmune diseasescardiovascular diseasesneurodegenerative diseasesinfectious diseasesendocrine diseasesgastrointestinal diseasesnephrological diseasesrespiratory diseasesophthalmological diseases; pharmaceutical chemical preparations for pharmaceutical or medical purposesviruses for the treatment of cancerautoimmune diseasescardiovascular diseasesneurodegenerative diseasesinfectious diseasesendocrine diseasesgastrointestinal diseasesnephrological diseasesrespiratory diseasesophthalmological diseases
Class 9
Chromatography apparatus for laboratory use
Class 10
Medical apparatus for use in treating of cancerautoimmune diseasescardiovascular diseasesneurodegenerative diseasesinfectious diseasesendocrine diseasesgastrointestinal diseasesnephrological diseasesrespiratory diseasesophthalmological diseases; surgical implants comprising artificial material
Class 42
Science and technology services being research and development in the pharmaceutical and biotechnology fields; pharmaceutical formulationspharmaceutical ingredientsrecombinant proteinsviruses and vaccines research and development; industrial analysis and research services in the field of pharmaceutical formulationspharmaceutical ingredientsrecombinant proteinsviruses and vaccines
Publications
History of USPTO decisions and trademark events.
27 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
09/26/2023
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
08/24/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/24/2023
IUCN
NOTICE OF ALLOWANCE CANCELLED
07/25/2023
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
07/25/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/25/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/30/2023
PUBO
PUBLISHED FOR OPPOSITION
05/30/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/10/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/25/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/07/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/06/2023
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
04/06/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
03/05/2023
GNFR
FINAL REFUSAL E-MAILED
03/05/2023
CNFR
FINAL REFUSAL WRITTEN
03/05/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/27/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/27/2023
ALIE
ASSIGNED TO LIE
01/26/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/28/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/02/2022
GNRT
NON-FINAL ACTION E-MAILED
06/02/2022
CNRT
NON-FINAL ACTION WRITTEN
06/02/2022
DOCK
ASSIGNED TO EXAMINER
06/02/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/13/2021
NWAP
NEW APPLICATION ENTERED
09/01/2021
Continuous trademark protection
Get notified about every new filing that threatens LEUKOCARE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.